WeVote
Log In

Bill

Bill

SB 1064

Medicaid Pharmacy Discounted Drug Prices

2025 Regular Session Introduced by Jay Collins

Bill would have allowed Florida Medicaid to directly negotiate prescription drug prices with manufacturers to reduce state healthcare spending.

Died in Health Policy
#subjectindex
0
WeVote Research Nonpartisan
Bill Summary · SB 1064

Legislative bill overview

SB 1064 would have authorized Florida's Medicaid program to negotiate directly with pharmaceutical manufacturers for discounted drug prices, similar to mechanisms used by Medicare. The bill aimed to reduce state spending on prescription medications by leveraging Medicaid's purchasing power to secure lower costs than currently available.

Why is this important

Florida's Medicaid program serves over 4 million beneficiaries and spends billions annually on prescription drugs. Direct negotiation authority could reduce state budget pressures on healthcare spending, potentially freeing resources for other Medicaid services or reducing taxpayer burden. However, it also raises questions about drug manufacturer pricing strategies and broader pharmaceutical market effects.

Potential points of contention

  • Pharmaceutical industry opposition: Drug manufacturers typically resist price negotiation authority, arguing it reduces innovation incentives and may limit patient access to newer medications
  • Federal-state authority questions: Uncertainty about whether states can independently negotiate Medicaid drug prices without federal authorization or coordination with existing federal programs
  • Market effects concerns: Critics worry aggressive state negotiations could destabilize pharmaceutical markets or create pricing inconsistencies across states, while supporters argue it corrects market failures in drug pricing

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.